Prucalopride
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prucalopride: From Constipation Disorder to Hypoalphalipoproteinemia
One-Sentence Summary
Prucalopride is a selective 5-HT4 receptor agonist originally used to treat constipation disorder. The TxGNN model predicts it may be effective for hypoalphalipoproteinemia (low HDL cholesterol), but this is a TxGNN model (deep learning) prediction only, with 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constipation disorder |
| Predicted New Indication | Hypoalphalipoproteinemia |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, prucalopride is a selective 5-HT4 receptor agonist that enhances gut motility, and its efficacy in constipation disorder is established.
For hypoalphalipoproteinemia, however, no mechanistic link can be identified. No established pathway connects 5-HT4 agonism to HDL metabolism. The very high TxGNN score (0.9982) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological or clinical evidence, and should be treated as a hypothesis-generating signal only.
Other top-ranked predictions show the same pattern. Most lipid disorders (homozygous familial hypercholesterolemia, familial combined hyperlipidemia), infections (oral candidiasis, strongyloidiasis, HIV) and duodenal ulcer have no plausible mechanistic basis. The only partially plausible direction is amyloidosis-related gut dysmotility (amyloidosis, primary amyloidosis), where a prokinetic might give symptomatic relief of intestinal pseudo-obstruction without treating the underlying disease. These have only indirect literature support (a case report and a motility-diagnosis study, neither testing prucalopride).
India Market Information
Prucalopride has 20 valid single-ingredient registrations in India, all oral tablets. Approved indication text is not available for these registrations. Main examples:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 174899 | Prudac 1 Tablet (Zydus Cadila) | Strip of 10 tablets | Not specified |
| 174283 | Prusent 1mg Tablet (Lupin Ltd) | Strip of 10 tablets | Not specified |
| 39195 | Convio 2mg Tablet (Wellvio Healthcare Pvt Ltd) | Strip of 10 tablets | Not specified |
| 174810 | Prucapla 1mg Tablet (Cipla Ltd) | Strip of 10 tablets | Not specified |
| 176052 | Prucalor 2mg Tablet (Ajanta Pharma Ltd) | Strip of 10 tablets | Not specified |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): ulcerative colitis, inflammatory bowel disease, intestinal perforation.
- Drug Interactions: 98 interactions are recorded. Examples include:
- Moderate: aclidinium, levonorgestrel, norethisterone, ethinylestradiol, and anticholinergics such as hyoscyamine, atropine, benztropine, biperiden, glycopyrronium and clidinium.
- Minor: nifedipine, afatinib, alpelisib, amiodarone, cobicistat, captopril, diltiazem, spironolactone, carvedilol and conivaptan.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication hypoalphalipoproteinemia has no clinical trials, no literature and no plausible mechanistic link to 5-HT4 agonism, so the high TxGNN score is not backed by evidence (Evidence Level L5).
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian market, which are needed for safety screening
- Detailed mechanism of action data
- A credible biological rationale linking 5-HT4 agonism to HDL metabolism, supported by preclinical data
- Consideration of the amyloidosis-related gut dysmotility direction (the only partially plausible candidate, ranked as a research question) in place of the top-ranked lipid prediction, along with controlled studies of prucalopride in that setting
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.